Total Payments
$2,020
2023 Payments
$243.15
Companies
9
Transactions
83
Medicare Patients
3,166
Medicare Billing
$268,276
Payment Breakdown by Category
Food & Beverage$2,020 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,020 | 83 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $741.29 | 63 | $0 (2022) |
| Amgen Inc. | $346.55 | 5 | $0 (2023) |
| Lilly USA, LLC | $309.95 | 6 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $216.78 | 3 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $119.56 | 1 | $0 (2017) |
| GENZYME CORPORATION | $100.65 | 1 | $0 (2017) |
| Radius Health, Inc. | $96.52 | 1 | $0 (2019) |
| Corcept Therapeutics | $64.67 | 2 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $23.75 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $243.15 | 3 | Lilly USA, LLC ($131.58) |
| 2022 | $450.97 | 17 | Novo Nordisk Inc ($280.24) |
| 2021 | $311.32 | 23 | Novo Nordisk Inc ($215.26) |
| 2020 | $41.43 | 2 | Amgen Inc. ($41.43) |
| 2019 | $335.11 | 31 | Novo Nordisk Inc ($141.59) |
| 2018 | $96.55 | 1 | Amgen Inc. ($96.55) |
| 2017 | $541.19 | 6 | Janssen Pharmaceuticals, Inc ($216.78) |
All Payment Transactions
83 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $8.71 | General |
| Category: Diabetes | ||||||
| 06/01/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $122.87 | General |
| Category: Diabetes | ||||||
| 02/16/2023 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $111.57 | General |
| Category: Bone Health | ||||||
| 10/27/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $96.93 | General |
| Category: Diabetes | ||||||
| 08/05/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $5.09 | General |
| Category: Diabetes | ||||||
| 06/28/2022 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Diabetes | ||||||
| 06/23/2022 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/17/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $5.18 | General |
| Category: Diabetes | ||||||
| 05/24/2022 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Diabetes | ||||||
| 05/19/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Diabetes | ||||||
| 05/17/2022 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $75.65 | General |
| Category: Diabetes | ||||||
| 05/13/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $4.44 | General |
| Category: Diabetes | ||||||
| 05/06/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $4.81 | General |
| Category: Diabetes | ||||||
| 04/22/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $3.34 | General |
| Category: Diabetes | ||||||
| 04/05/2022 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.72 | General |
| Category: Diabetes | ||||||
| 04/01/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $4.28 | General |
| Category: Diabetes | ||||||
| 03/04/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $3.87 | General |
| Category: Diabetes | ||||||
| 03/04/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $3.53 | General |
| Category: Diabetes | ||||||
| 02/11/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $4.28 | General |
| Category: Diabetes | ||||||
| 01/18/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: Diabetes | ||||||
| 12/21/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Diabetes | ||||||
| 12/03/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $3.99 | General |
| Category: Diabetes | ||||||
| 12/03/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $2.89 | General |
| Category: Diabetes | ||||||
| 11/16/2021 | Lilly USA, LLC | BAQSIMI (Drug) | Food and Beverage | In-kind items and services | $31.39 | General |
| Category: Diabetes | ||||||
| 11/05/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $4.40 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 752 | 1,000 | $315,744 | $69,891 |
| 2022 | 11 | 831 | 1,123 | $326,093 | $81,981 |
| 2021 | 9 | 747 | 942 | $247,362 | $66,188 |
| 2020 | 10 | 836 | 1,023 | $214,358 | $50,216 |
Total Patients
3,166
Total Services
4,088
Medicare Billing
$268,276
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 387 | 584 | $200,633 | $44,371 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 150 | 160 | $39,024 | $7,961 | 20.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 75 | 75 | $36,975 | $7,311 | 19.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 42 | $9,153 | $2,880 | 31.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $6,013 | $1,690 | 28.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 23 | 37 | $4,437 | $1,585 | 35.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 21 | 21 | $7,014 | $1,433 | 20.4% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Facility | 2023 | 12 | 13 | $4,078 | $824.85 | 20.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 22 | 23 | $3,110 | $636.30 | 20.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 11 | 11 | $2,037 | $629.64 | 30.9% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2023 | 12 | 19 | $3,270 | $569.43 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 363 | 564 | $179,480 | $45,917 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 93 | 93 | $44,334 | $10,148 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 156 | 166 | $36,800 | $8,548 | 23.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 39 | 81 | $17,160 | $5,008 | 29.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 21 | $12,273 | $3,601 | 29.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 40 | 42 | $8,827 | $2,987 | 33.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 36 | 36 | $11,518 | $2,024 | 17.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 28 | 55 | $6,433 | $1,837 | 28.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 19 | 19 | $2,755 | $891.57 | 32.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2022 | 17 | 26 | $4,690 | $799.15 | 17.0% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 20 | 20 | $1,823 | $220.71 | 12.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 275 | 376 | $115,830 | $30,273 | 26.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 213 | 241 | $51,893 | $12,993 | 25.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 86 | 106 | $21,348 | $7,724 | 36.2% |
About Dr. Leo Tchong, MD
Dr. Leo Tchong, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Burlington, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1861655136.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leo Tchong, MD has received a total of $2,020 in payments from pharmaceutical and medical device companies, with $243.15 received in 2023. These payments were reported across 83 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($2,020).
As a Medicare-enrolled provider, Tchong has provided services to 3,166 Medicare beneficiaries, totaling 4,088 services with total Medicare billing of $268,276. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Burlington, MA
- Active Since 07/08/2008
- Last Updated 04/09/2012
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1861655136
Products in Payments
- Ozempic (Drug) $547.92
- EVENITY (Biological) $250.00
- MOUNJARO (Drug) $228.51
- INVOKANA (Drug) $216.78
- SOLIQUA (Drug) $119.56
- Tresiba (Drug) $104.20
- THYROGEN (Drug) $100.65
- Prolia (Biological) $96.55
- Tymlos (Biological) $96.52
- Korlym (Drug) $64.67
- Rybelsus (Drug) $59.60
- BAQSIMI (Drug) $31.39
- RYBELSUS (Drug) $29.57
- JARDIANCE (Drug) $26.72
- LEQVIO (Drug) $23.75
- TRULICITY (Drug) $23.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Burlington
Dr. Thomas O'connell, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $987,161
Endocrinology, Diabetes & Metabolism $987,161
Dr. John Leahy, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $152,041
Endocrinology, Diabetes & Metabolism $152,041
M. James Lenhard, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $128,529
Endocrinology, Diabetes & Metabolism $128,529
Dr. Shamil Morayati, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $10,826
Endocrinology, Diabetes & Metabolism $10,826
Angela Restrepo, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $458.66
Endocrinology, Diabetes & Metabolism $458.66
Sathyavani Prabhakar, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $420.76
Endocrinology, Diabetes & Metabolism $420.76